Catalyst Wire Dossier Catalyst Wire Dossier

Talacotuzumab

talacotuzumab · Janssen Research & Development, LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Talacotuzumab, covering 2020-03-13 to 2020-03-13. Get the full timeline:

Most recent: Clinical Trial Update: Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment [Phase 2]

See pricing